In vitro targeting of Polo-like kinase 1 in bladder carcinoma: Comparative effects of four potent inhibitors

Cancer Biology and Therapy

Volumn 14, Issue 7, 2013, Pages 648-657

  Brassesco, María Sol ^a   Pezuk, Julia Alejandra ^a   Morales, Andressa Gois ^a   De Oliveira, Jaqueline Carvalho ^a   Roberto, Gabriela Molinari ^a   Da Silva, Glenda Nicioli ^a   De Oliveira, Harley Francisco ^b   Scrideli, Carlos Alberto ^a   Tone, Luiz Gonzaga ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Bladder cancer; Cell lines; PLK1 inhibition

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; CISPLATIN; DOXORUBICIN; GSK 461364; GW 843682X; METHOTREXATE; POLO LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VOLASERTIB;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL INVASION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; PROTEIN TARGETING; RADIOSENSITIVITY; RADIOSENSITIZATION; TUMOR CELL; TUMOR INVASION;

BLADDER CANCER; CELL LINES; PLK1 INHIBITION;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84881135644     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25087     Document Type: Article

References (43)

1. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100: 1672-94; PMID:19033571; http://dx.doi.org/10.1093/jnci/djn389
2. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461-9; PMID:3343727
3. Kaufman DS. Challenges in the treatment of bladder cancer. Ann Oncol 2006; 17(Suppl 5): v106-12; PMID:16807436; http://dx.doi.org/10.1093/annonc/ mdj963
4. Yamamoto Y, Matsuyama H, Kawauchi S, Matsumoto H, Nagao K, Ohmi C, et al. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006; 70: 231-7; PMID:16837776; http://dx.doi.org/10. 1159/000094416
5. Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol 2011; PMID:22192978
6. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9: 643-60; PMID:20671765; http://dx.doi.org/10.1038/nrd3184
7. Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, Segersten U, et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol 2012; 180: 1824-34; PMID:22449953; http://dx.doi.org/10.1016/j. ajpath.2012.01.023
8. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-22; PMID:17291758; http://dx.doi.org/10.1016/j.cub.2006.12.037
9. Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009; 129: 2843-53; PMID:19554017; http://dx.doi.org/10.1038/jid.2009.172
10. Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 2005; 24: 260-6; PMID:15640841; http://dx.doi.org/10.1038/sj.onc.1208219
11. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005; 115: 978-85; PMID:15761500
12. Seth S, Matsui Y, Fosnaugh K, Liu Y, Vaish N, Adami R, et al. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther 2011; 19: 928-35; PMID:21364537; http://dx.doi.org/10.1038/mt.2011.21
13. Renner AG, Dos Santos C, Recher C, Bailly C, Créancier L, Kruczynski A, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009; 114: 659-62; PMID:19458358; http://dx.doi.org/10.1182/blood- 2008-12-195867
14. Morales AG, Brassesco MS, Pezuk JA, Oliveira JC, Montaldi AP, Sakamoto-Hojo ET, et al. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anticancer Drugs 2011; 22: 995-1001; PMID:21822121
15. Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, et al. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Anticancer Drugs 2011; 22: 444-53; PMID:21399492; http://dx.doi.org/10.1097/CAD.0b013e32834513f4
16. Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009; 129: 2843-53; PMID:19554017; http://dx.doi.org/10.1038/jid.2009.172
17. Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009; 23: 1564-76; PMID:19421227; http://dx.doi.org/10. 1038/leu.2009.94
18. Plyte S, Musacchio A. PLK1 inhibitors: setting the mitotic death trap. Curr Biol 2007; 17: R280-3; PMID:17437704; http://dx.doi.org/10.1016/j.cub.2007. 02.018
19. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008; 15: 1153-62; PMID:18404154; http://dx.doi.org/10.1038/cdd.2008.47
20. Reznikoff CA, Belair CD, Yeager TR, Savelieva E, Blelloch RH, Puthenveettil JA, et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996; 23: 571-84; PMID:8893868
21. da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos Júnior GA, Sakamoto-Hojo ET, Salvadori DM. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med (Maywood) 2010; 235: 814-24; PMID:20558835; http://dx.doi.org/10.1258/ebm.2010.009322
22. Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 2010; 70: 1513-23; PMID:20145140; http://dx.doi.org/10.1158/0008-5472.CAN- 09-2181
23. Wolf S, Lorenz J, Mössner J, Wiedmann M. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World J Gastroenterol 2010; 16: 156-66; PMID:20066734; http://dx.doi.org/10.3748/wjg. v16.i2.156
24. Stewart HJ, Kishikova L, Powell FL, Wheatley SP, Chevassut TJ. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. Exp Hematol 2011; 39: 330-8; PMID:21184800; http://dx.doi.org/10.1016/j.exphem.2010.12.006
25. Didier C, Cavelier C, Quaranta M, Demur C, Ducommun B. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia. Eur J Pharmacol 2008; 591: 102-5; PMID:18616938; http://dx.doi.org/ 10.1016/j.ejphar.2008.06.062
26. Deckbar D, Jeggo PA, Löbrich M. Understanding the limitations of radiation-induced cell cycle checkpoints. Crit Rev Biochem Mol Biol 2011; 46: 271-83; PMID:21524151; http://dx.doi.org/10.3109/10409238. 2011.575764
27. Rödel F, Keppner S, Capalbo G, Bashary R, Kaufmann M, Rödel C, et al. Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol 2010; 177: 918-29; PMID:20581060; http://dx.doi.org/10.2353/ajpath.2010.100040
28. Bordon E, Leon LG, Rios-Luci C, Lara PC, Padron JM. In vitro synergistic interaction between DTA0100 and radiation in human cancer cell lines. Anticancer Agents Med Chem 2012; 12: 988-93; PMID:22339062; http://dx.doi.org/10.2174/ 187152012802650057
29. Heravi M, Tomic N, Liang L, Devic S, Holmes J, Deblois F, et al. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. Anticancer Drugs 2012; 23: 525-33; PMID:22357220; http://dx.doi.org/10.1097/CAD.0b013e32834ea5b3
30. Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, et al. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010; 77: 253-60; PMID:20394857; http://dx.doi.org/10.1016/j.ijrobp.2009.11.027
31. Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, et al. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer 2012; 12: 80; PMID:22390279; http://dx.doi.org/10.1186/1471-2407-12-80
32. Qian Y, Hua E, Bisht K, Woditschka S, Skordos KW, Liewehr DJ, et al. Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clin Exp Metastasis 2011; 28: 899-908; PMID:21953073; http://dx.doi.org/10.1007/s10585-011-9421-9
33. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II - results of EORTC study 30986. J Clin Oncol 2009; 27: 5634-9; PMID:19786668; http://dx.doi.org/ 10.1200/JCO.2008.21.4924
34. Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 2010; 46: 2206-15; PMID:20471824; http://dx.doi.org/10.1016/j.ejca.2010.03.039
35. Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, et al. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia 2012; 14: 410-9; PMID:22745587
36. Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012; 48: 179-86; PMID:22119200; http://dx.doi.org/10.1016/j.ejca.2011.11.001
37. Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2011; 17: 3420-30; PMID:21459796; http://dx.doi.org/10.1158/1078-0432.CCR-10-2946
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262
39. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1: 2315-9; PMID:17406473; http://dx.doi.org/10.1038/nprot.2006.339
40. Lee YJ, Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem 1999; 274: 19792-8; PMID:10391922; http://dx.doi.org/10.1074/ jbc.274.28.19792
41. Pauwels B, Korst AE, de Pooter CM, Pattyn GG, Lambrechts HA, Baay MF, et al. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol 2003; 51: 221-6; PMID:12655440
42. Tao Y, Zhang P, Frascogna V, Lecluse Y, Auperin A, Bourhis J, et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007; 97: 1664-72; PMID:18026198; http://dx.doi.org/10.1038/sj.bjc. 6604083
43. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55; PMID:6382953; http://dx.doi.org/10.1016/0065-2571(84)90007-4